Cerity Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $73.6M | Sell |
1,277,451
-115,322
| -8% | -$6.62M | 0.09% | 193 |
|
|
2026
Q1 | $84.5M | Sell |
1,392,773
-24,573
| -2% | -$1.43M | 0.12% | 161 |
|
|
2025
Q4 | $76.5M | Buy |
1,417,346
+475,076
| +50% | +$22.9M | 0.11% | 170 |
|
|
2025
Q3 | $42.5M | Buy |
942,270
+79,647
| +9% | +$3.72M | 0.07% | 234 |
|
|
2025
Q2 | $39.9M | Sell |
862,623
-51,068
| -6% | -$2.51M | 0.07% | 228 |
|
|
2025
Q1 | $55.7M | Buy |
913,691
+10,987
| +1% | +$640K | 0.11% | 176 |
|
|
2024
Q4 | $49.4M | Buy |
902,704
+11,399
| +1% | +$637K | 0.11% | 175 |
|
|
2024
Q3 | $46.1M | Buy |
891,305
+249,475
| +39% | +$11.7M | 0.1% | 181 |
|
|
2024
Q2 | $26.7M | Sell |
641,830
-241,589
| -27% | -$10.8M | 0.07% | 237 |
|
|
2024
Q1 | $47.3M | Buy |
883,419
+507,727
| +135% | +$25.9M | 0.12% | 166 |
|
|
2023
Q4 | $19.3M | Buy |
375,692
+54,351
| +17% | +$2.85M | 0.06% | 252 |
|
|
2023
Q3 | $18.7M | Sell |
321,341
-292,888
| -48% | -$17.9M | 0.09% | 201 |
|
|
2023
Q2 | $39.3M | Buy |
614,229
+70,722
| +13% | +$4.74M | 0.15% | 135 |
|
|
2023
Q1 | $42.1M | Buy |
543,507
+70,677
| +15% | +$4.98M | 0.1% | 146 |
|
|
2022
Q4 | $34.7M | Buy |
472,830
+184,763
| +64% | +$13.9M | 0.22% | 100 |
|
|
2022
Q3 | $20.5M | Sell |
288,067
-3,596
| -1% | -$261K | 0.25% | 84 |
|
|
2022
Q2 | $22.5M | Buy |
291,663
+45,040
| +18% | +$3.43M | 0.25% | 82 |
|
|
2022
Q1 | $17.4M | Buy |
246,623
+29,495
| +14% | +$1.98M | 0.27% | 73 |
|
|
2021
Q4 | $13.5M | Buy |
217,128
+21,173
| +11% | +$1.24M | 0.21% | 96 |
|
|
2021
Q3 | $11.6M | Buy |
195,955
+17,766
| +10% | +$1.17M | 0.26% | 85 |
|
|
2021
Q2 | $11.9M | Sell |
178,189
-156
| -0.1% | -$10.2K | 0.26% | 79 |
|
|
2021
Q1 | $11.3M | Sell |
178,345
-37,814
| -17% | -$2.35M | 0.27% | 79 |
|
|
2020
Q4 | $13.4M | Buy |
216,159
+48,022
| +29% | +$2.95M | 0.43% | 48 |
|
|
2020
Q3 | $10.1M | Buy |
168,137
+82,981
| +97% | +$4.99M | 0.42% | 49 |
|
|
2020
Q2 | $5.01M | Buy |
85,156
+34,792
| +69% | +$2.08M | 0.28% | 69 |
|
|
2020
Q1 | $2.81M | Sell |
50,364
-5,414
| -10% | -$331K | 0.18% | 107 |
|
|
2019
Q4 | $3.58M | Buy |
55,778
+10,402
| +23% | +$596K | 0.18% | 99 |
|
|
2019
Q3 | $2.3M | Sell |
45,376
-844
| -2% | -$39.7K | 0.14% | 147 |
|
|
2019
Q2 | $2.1M | Sell |
46,220
-4,466
| -9% | -$208K | 0.13% | 148 |
|
|
2019
Q1 | $2.42M | Sell |
50,686
-1,382
| -3% | -$68.8K | 0.16% | 145 |
|
|
2018
Q4 | $2.71M | Buy |
52,068
+338
| +0.7% | +$18.2K | 0.18% | 127 |
|
|
2018
Q3 | $3.21M | Buy |
51,730
+3,028
| +6% | +$180K | 0.22% | 116 |
|
|
2018
Q2 | $2.69M | Buy |
48,702
+680
| +1% | +$36.7K | 0.2% | 124 |
|
|
2018
Q1 | $3.04M | Sell |
48,022
-6,649
| -12% | -$428K | 0.23% | 114 |
|
|
2017
Q4 | $3.35M | Buy |
54,671
+2,354
| +4% | +$147K | 0.22% | 103 |
|
|
2017
Q3 | $3.33M | Sell |
52,317
-114,103
| -69% | -$6.66M | 0.24% | 97 |
|
|
2017
Q2 | $5.92M | Buy |
166,420
+122,290
| +277% | +$6.65M | 0.5% | 40 |
|
|
2017
Q1 | $2.4M | Buy |
+44,130
| New | +$2.42M | 0.2% | 103 |
|
Other funds holding BMY
VCM
VPM
Cerity Partners's BMY Position: Q2 2026 in Review
Cerity Partners reduced its Bristol-Myers Squibb (BMY) stake by 8.3% in Q2 2026, selling an estimated $6.62M and leaving 1,277,451 shares worth $73.6M. The position accounts for 0.09% of the portfolio, ranked #193.
Cerity Partners first reported a position in BMY in Q1 2017 and has held it in 38 quarters since. The position peaked at $84.5M in Q1 2026. 2,309 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Cerity Partners held 1,277,451 shares of Bristol-Myers Squibb worth $73.6M as of Q2 2026.
- Cerity Partners sold 115,322 Bristol-Myers Squibb shares in Q2 2026, an estimated $6.62M.
- Bristol-Myers Squibb made up 0.09% of Cerity Partners's portfolio in Q2 2026, its #193 holding.
- Cerity Partners first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 38 quarters since.
- Cerity Partners's Bristol-Myers Squibb position peaked at $84.5M in Q1 2026.
- 2,309 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.